The enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy—a randomized controlled trial

ABSTRACT:

Hyperbilirubinemia is one of the most common diseases in neonates, and phototherapy is currently the most commonly used treatment in medicine, but previous studies have found that phototherapy can lead to changes in the intestinal flora of jaundice neonates, especially bifidobacteria. The focus of this study is whether the precise addition of bifidobacteria can alleviate the intestinal microbiota disorder caused by phototherapy and improve the clinical outcomes of jaundice neonates. In this study, two strains of Bifidobacterium derived from healthy infants were added to jaundice neonates receiving phototherapy, and the effects of probiotics on the improvement of clinical symptoms, intestinal microbiota structure and metabolic indexes, and intestinal inflammatory factors in jaundice neonates during phototherapy were investigated. For neonates receiving phototherapy, the addition of M-16V+Bb-12 probiotics can improve the diversity of microflora, reduce the fixed value of harmful bacteria in the intestine, and enhance the excretion of bilirubin from the intestine, so as to improve the inflammatory damage and microbiota disorder caused by phototherapy, and achieve the effect of clinically improving jaundice, reducing bilirubin, shortening the length of hospitalization, and promoting neurodevelopment. It provides a safer and more effective treatment for neonatal jaundice.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS14123 | MetaboLights | 2026-03-26

REPOSITORIES: MetaboLights